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Exosomes derived from bone marrow mesenchymal stem cells harvested
from type two diabetes rats promotes neurorestorative effects after stroke in
type two diabetes rats
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Background and purpose: Diabetes elevates the risk of stroke, promotes inflammation, and exacerbates vascular
and white matter damage post stroke, thereby hindering long term functional recovery. Here, we investigated
the neurorestorative effects and the underlying therapeutic mechanisms of treatment of stroke in type 2 diabetic
rats (T2DM) using exosomes harvested from bone marrow stromal cells obtained from T2DM rats (T2DM-MSCExo).
Methods: T2DM was induced in adult male Wistar rats using a combination of high fat diet and Streptozotocin.
Rats were subjected to transient 2 h middle cerebral artery occlusion (MCAo) and 3 days later randomized to one
of the following treatment groups: 1) phosphate-buffered-saline (PBS, i.v), 2) T2DM-MSC-Exo, (3 × 1011, i.v), 3)
T2DM-MSC-Exo with miR-9 over expression (miR9+/+-T2DM-MSC-Exo, 3 × 1011, i.v) or 4) MSC-Exo derived
from normoglycemic rats (Nor-MSC-Exo) (3 × 1011, i.v). T2DM sham control group is included as reference.
Rats were sacrificed 28 days after MCAo.
Results: T2DM-MSC-Exo treatment does not alter blood glucose, lipid levels, or lesion volume, but significantly
improves neurological function and attenuates post-stroke weight loss compared to PBS treated as well as NorMSC-Exo treated T2DM-stroke rats. Compared to PBS treatment, T2DM-MSC-Exo treatment of T2DM-stroke rats
significantly 1) increases tight junction protein ZO-1 and improves blood brain barrier (BBB) integrity; 2)
promotes white matter remodeling indicated by increased axon and myelin density, and increases oligodendrocytes and oligodendrocyte progenitor cell numbers in the ischemic border zone as well as increases primary
cortical neuronal axonal outgrowth; 3) decreases activated microglia, M1 macrophages, and inflammatory
factors MMP-9 (matrix mettaloproteinase-9) and MCP-1 (monocyte chemoattractant protein-1) expression in the
ischemic brain; and 4) decreases miR-9 expression in serum, and increases miR-9 target ABCA1 (ATP-binding
cassette transporter 1) and IGFR1 (Insulin-like growth factor 1 receptor) expression in the brain. MiR9+/
+-T2DM-MSC-Exo treatment significantly increases serum miR-9 expression compared to PBS treated and
T2DM-MSC-Exo treated T2DM stroke rats. Treatment of T2DM stroke with miR9+/+-T2DM-MSC-Exo fails to
improve functional outcome and attenuates T2DM-MSC-Exo treatment induced white matter remodeling and
anti-inflammatory effects in T2DM stroke rats.
Conclusions: T2DM-MSC-Exo treatment for stroke in T2DM rats promotes neurorestorative effects and improves
functional outcome. Down regulation of miR-9 expression and increasing its target ABCA1 pathway may

Abbreviations: ABCA1, Adenosine triphosphate-binding cassette transporter 1; ANOVA, Analysis of Variance; APC, Adenomatous polyposis coli; BBB, Blood brain
barrier; CNPase, 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, a prenylated myelin protein; DAPI, 4′,6-diamidino-2-phenylindole, used as a nuclear counterstaining;
ECA, External carotid artery; GFAP, Glial fibrillary acidic protein; HFD, High fat diet; IBA1, Ionizing calcium-Binding Adaptor molecule 1; IBZ, Ischemic boundary
zone; IGFR1, Insulin-like growth factor1 receptor 1; ISH, In situ hybridization; MCAo, Middle cerebral artery occlusion; MCP1, Monocyte chemoattractant protein 1;
MiR, MicroRNA; MMP9, Matrix mettaloproteinase-9; mNSS, Modified neurological severity score; mRNA, messenger RNA; MSC, Bone marrow stromal cells; MSCExo, Exosomes derived from MSCs; NeuN, Neuronal nuclear antigen; NG2, Neural/glial antigen 2; Nor-MSC-Exo, Exosomes derived from MSCs of normoglycemic
animals; OGD, Oxygen glucose deprivation; OL, Oligodendrocyte; OPC, Oligodendrocyte progenitor cell; PCN, Primary cortical neurons; STZ, Streptozotocin; T2DM,
Type 2 diabetes mellitus; T2DM-MSC-Exo, Exosomes derived from bone marrow cells of T2DM rats; vWF, von Willebrand factor; ZO-1, Zona occludens-1
⁎
Corresponding authors.
E-mail addresses: pvenkat3@hfhs.org (P. Venkat), jchen4@hfhs.org (J. Chen).
https://doi.org/10.1016/j.expneurol.2020.113456
Received 1 May 2020; Received in revised form 8 July 2020; Accepted 30 August 2020
Available online 02 September 2020
0014-4886/ © 2020 Elsevier Inc. All rights reserved.

Experimental Neurology 334 (2020) 113456

P. Venkat, et al.

contribute partially to T2DM-MSC-Exo treatment induced white matter remodeling and anti-inflammatory responses.

1. Introduction

been implicated to exert protective as well as adverse effects under
various disease conditions (Coolen et al., 2013). In patients with prediabetes or T2DM, significantly increased miR-9 expression in peripheral blood has been reported (Al-Muhtaresh and Al-Kafaji, 2018). Increased serum miR-9 expression has also been associated with poor
prognosis in diabetic nephropathy (Xiao et al., 2017). Increased expression of miR-9 in serum exosomes of acute ischemic stroke patients
has been identified as a potential disease biomarker, and is associated
with stroke severity (Ji et al., 2016). Previous studies have demonstrated that treatment of stroke with exosomes derived from MSCs of
non-diabetic animals (MSC-Exo) improves neurological function in nondiabetic stroke animals (Xin et al., 2012a; Xin et al., 2013a; Xin et al.,
2013b). We have also demonstrated that MSCs derived from diabetic
rats promotes neurorestorative effects after stroke in T1DM rats (Cui
et al., 2016). However, whether exosomes derived from bone marrow
cells of T2DM rats (T2DM-MSC-Exo) can be employed to treat stroke in
T2DM rats has not been investigated. In this study, we are the first to
investigate the therapeutic efficacy and underlying mechanisms of
stroke treatment in T2DM rats with T2DM-MSC-Exo.

Stroke is predominantly a vascular disease with devastating neurological aftermath, often resulting in long term disability or death.
Despite a trend of declining ischemic stroke incidence in the United
States as well as globally largely due to control of risk factors such as
hypertension and smoking (Vangen-Lønne Anne et al., 2017), there is a
dramatic worldwide increase in incidence of type 2 diabetes mellitus
(T2DM) (Read et al., 2018). Diabetes increases the risk of stroke by 3 to
4 fold, and approximately 30% of stroke patients suffer from diabetes
(Ergul et al., 2016; Mast et al., 1995; Megherbi et al., 2003). Treating
diabetic stroke patients is challenging due to the extensive damage they
sustain to the cerebral vasculature, exacerbated neurological deficits,
enhanced inflammatory responses and their susceptibility to recurrent
strokes (Callahan et al., 2011; Chen et al., 2011b; Chen et al., 2011c).
Pre-clinical studies have indicated that therapeutic strategies that are
successful in non-diabetic stroke may not readily translate to diabetic
stroke treatment (Chen et al., 2011d; Ning et al., 2012). Thus, there is a
compelling need to develop therapeutic strategies specifically to improve neurological function after stroke in the diabetic population.
Ischemic stroke induced neural damage and death is rapid, thereby
challenging neuroprotective strategies with a narrow intervention time
frame. Even when T2DM stroke patients receive timely thrombolytic
intervention, they still face an increased risk of death, intracerebral
hemorrhage and unfavorable 90-day outcome proportional to admission hyperglycemia (Poppe et al., 2009). Treatment of stroke using cell
therapy is emerging as a promising treatment option, particularly at
delayed time points (Chen et al., 2014; Sarmah et al., 2018). Spontaneous recovery driven by endogenous brain remodeling that occur post
stroke may be amplified by exogenously administered neurorestorative
agents, such as cell therapy (Chen et al., 2014). Among the cells used
for post stroke therapy, bone marrow stromal cells (MSC) have great
potential as therapeutic agents in stroke management, as they are easily
obtained and can be rapidly expanded ex vivo for transplantation (Chen
et al., 2014; Deng et al., 2019; Otero-Ortega et al., 2019).
MSCs interact with and alter brain parenchymal cells via the secretion of trophic and growth factors as well as exosomes to exert
therapeutic effects (Otero-Ortega et al., 2019; Xin et al., 2012b). Exosomes are small extracellular vesicles (30–100 nm) that facilitate cellcell communication. Exosome therapy has several advantages over cell
therapy. Exosomes do not elicit immune rejection, do not have a vascular obstructive effect and have low risk of triggering tumors or malignant transformation (Xin et al., 2014). Facilitating clinical translation, a relatively large quantity of exosomes can be derived from a small
quantity of cells; exosomes are stable and can be stored until therapeutic need (Codispoti et al., 2018). Thus, systemic administration of
exosomes may be a means by which to deliver the active components of
cell-based therapy to the CNS (Moon et al., 2019; Xin et al., 2014; Xin
et al., 2013a). The release and transfer of exosomal cargo, which consists of proteins, lipids, and RNA molecules including messenger RNA
(mRNA) and microRNA (miR), can regulate protein synthesis within
recipient cells. MSCs then communicate with parenchymal cells via
microvesicles including exosomes which transfer miRs to recipient
cells.
MiRs are short sequences of non-coding RNA (ca. 22 nucleotides)
and post-transcriptionally regulate gene expression (Chen et al., 2014;
Moon et al., 2019; Otero-Ortega et al., 2019). MiRs can regulate many
genes, pathways, and biological networks, either acting alone or in
concert with other miRs (Chen et al., 2014). MiR-9 is among the highly
expressed miRs in the developing and adult vertebrate brain and has

2. Material and methods
All experiments were conducted in accordance with the standards
and procedures of the American Council on Animal Care and
Institutional Animal Care and Use Committee of Henry Ford Health
System. This manuscript has been prepared in accordance with ARRIVE
guidelines.
2.1. Diabetes induction
To induce T2DM in male adult Wistar rats (175-200 g, Charles
River), a combination of high fat diet (HFD, D12492, Research Diets)
for 2 weeks followed by single intraperitoneal injection of low dose
Streptozotocin (STZ, 35 mg/kg, Enzo) with continued HFD for another
2 weeks was employed. This widely accepted model of T2DM induces
metabolic characteristics of T2DM, such as high glucose, peripheral
insulin resistance and reduced β-cell mass (Islam and Loots du, 2009).
Two weeks after STZ injection, fasting blood glucose level was tested
using a glucose analyzer (AgaMatrix Advanced blood glucose monitoring system) and animals with fasting blood glucose > 300 mg/dl
were subjected to stroke. Fasting blood glucose was measured again
before sacrifice of animals to test the effect of treatment on glucose
modulation. Blood lipids and triglycerides were measured using CardioChek Plus analyzer (Fischer Scientific).
2.2. Middle cerebral artery occlusion model
T2DM rats were subjected to transient (2 h) right middle cerebral
artery occlusion (MCAo) via intraluminal vascular occlusion, as previously described (Chen et al., 1992). Briefly, rats were anesthetized
with 2% isoflurane and maintained with 1.5 isoflurane in 70% N2O and
30% O2 by a face mask and regulated with a modified FLUOTEC 3
Vaporizer (Fraser Harlake). Rectal temperature was maintained at 37 °C
throughout the surgical procedure by means of a feedback-regulated
water heating system. A 4–0 nylon suture with its tip rounded by
heating near a flame was inserted into the external carotid artery (ECA).
The length of nylon suture, determined according to the animal's
weight, was gently advanced from the ECA into the lumen of the internal carotid artery until the suture blocked the origin of the MCA.
After 2 h of MCAo, animals were re-anesthetized, and the filament was
2
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gently withdrawn to restore blood flow.

reference. All treatments were administered once at 3 days after stroke.
Since the infarct volume is fully evolved, stroke treatment initiated at
this time point does not target decreasing lesion volume, but enhancing
functional outcome via neurorestorative effects (Saver, 2010). Also, a
majority of stroke patients can be treated at 3 days after stroke. Rats
were sacrificed 28 days after MCAo for immunostaining quantification
analysis.

2.3. MSC culture
Four normoglycemic rats and four rats with induced T2DM, as described above (fasting glucose > 300 mg/dl), were sacrificed and bone
marrow was obtained from the long bones (femurs and tibias). Bone
marrow cells were incubated at 37 °C with MSC culture medium (Chen
et al., 2001a). Non-adherent cells were removed at 72 h and fresh
medium was added. On day 7–10, adherent cells were recovered by
trypsinization and cells were re-plated at a density of 5 × 106 cells per
dish. MSC cultures were maintained by replating cells when they reach
80–90% confluence.

2.8. Neurological function tests and exclusion criteria
An investigator was blinded to the experimental groups to perform a
battery of functional tests including adhesive removal test (Chen et al.,
2001b) and modified neurological severity score (mNSS) evaluation
(Chen et al., 2001b) before MCAo, and on days 1, 7, 14, 21 and 28 after
MCAo. Animals with mNSS scores < 6 (possibly small to no lesion)
or > 13 (poor survival) at 24 h after MCAo were excluded. Body weight
was recorded weekly.

2.4. MiR-9 transfection
A mixture of 100 μl Ingenio Electroporation Solution (Mirus) and
5 μl of rat rno-miR-9a-5p mimic (Dharmacon) was prepared. T2DMMSCs were harvested as described above, and 1–2 × 106 cells were resuspended in the electroporation solution. The cell solution was then
loaded into Ingenio cuvettes with a 0.2 cm gap (Mirus). The cuvettes
were stored on ice until they were loaded into the amaxa nucleofection
machine (Lonza). The program run for the electroporation depended on
the cell type being transfected (rat MSC used U023). After electroporation, cells were removed from the cuvettes and put into culture and
allowed to grow for 24 h at which point the media was changed to
media containing exosome depleted FBS and cells were cultured for
48 h. Following miR-9 transfection in DM-MSCs, we measured the expression of miR-9 using real time PCR and found that miR9+/+DMMSCs have significantly elevated miR-9 expression compared to DMMSCs (Supplementary Fig. 1).

2.9. Immunohistochemical assessment
Brains were fixed using transcardial perfusion with saline, followed
by perfusion and immersion in 4% paraformaldehyde. The brains were
then embedded in paraffin and a standard block was obtained from the
center of the lesion (bregma −2 mm ~ +2 mm). A series of 6 μm thick
sections cut from the block were then prepared and antibody against
specific protein of interest in this project used. To measure ischemic
lesion volume, Hematoxylin-eosin (H&E) staining was employed and 7
brain sections were traced with the use of MCID image analysis system
(Imaging Research). The indirect lesion area, in which the intact area of
the ipsilateral hemisphere is subtracted from the area of the contralateral hemisphere was calculated (Chen et al., 2001a). Infarction
volume is presented as a percentage of the lesion compared with the
contralateral hemisphere. Lesion volume measurement was performed
by an investigator blinded to the experimental groups.
Brain coronal tissue sections were prepared and antibody against
APC (adenomatous polyposis coli, oligodendrocyte (OL) marker,
Genway, 1:20), NG2 (neural/glial antigen 2, oligodendrocyte progenitor cell (OPC) marker, Chemicon (EMD Millipore), 1:400), ZO-1
(Zona occludens-1, Invitrogen, 1:500), ABCA1 (adenosine triphosphatebinding cassette transporter1, Novus, 1:200), IGFR1 (insulin-like
growth factor1 receptor 1, Santa Cruz, 1:100), CNPase (2′,3′-Cyclicnucleotide 3′-phosphodiesterase, a prenylated myelin protein,
Millipore, 1200), DAPI (4′,6-diamidino-2-phenylindole, used as a nuclear counterstaining, Vector Laboratories), GFAP (glial fibrillary acidic
protein, astrocytes marker, Aves, 1:500), NeuN (neuronal nuclear antigen, marker for neurons, Chemicon, 1:200), vWF (von Willebrand
factor, endothelial cell marker, 1:400; Dako), IBA1 (ionizing calciumBinding Adaptor molecule 1, activated microglia marker, dilution
1:1000, Wako), ED1 (microglia/macrophages marker, 1:30; AbD
Serotec), MMP-9 (matrix mettaloproteinase-9, 1:500, Santa Cruz
Biotechnology), and MCP-1 (monocyte chemoattractant protein 1) were
employed. Antibody against albumin (albumin-FITC, polyclonal, 1:500,
Abcam) was used to demonstrate blood brain barrier (BBB) leakage and
Prussian
blue
staining
used
to
evaluate
hemorrhage.
Bielschowsky‑silver staining was used to demonstrate axons and luxol
fast blue staining was used to demonstrate myelin. Control experiments
consisted of similar procedures without addition of primary antibody.
In situ hybridization (ISH) was performed using the miRCURY LNA
miRNA ISH Optimization Kit for formalin-fixed paraffin embedded
tissue samples (Qiagen) following manufacturer's protocol. Locked nucleic acid (LNA) probes against miR-9, U6-positive, and scrambled-negative probes (Exiqon) were used for ISH to detect mature miRs. All
probes were digoxigenin-labeled LNA probes at 25 nM in hybridization
buffer.

2.5. Exosome isolation
To isolate exosomes, culture media was filtered using a 0.22 μM
syringe filter (Millipore) to remove any particulate matter and then
Exoquick TC (System Biosciences) was added at the ratio of 2 ml
Exoquick/10 ml media. The media was stored overnight at 4 °C and
then centrifuged at 1500 g for 30 min. Supernatant was removed and
the pellet re-suspended in PBS. The protein concentration was determined using BCA Protein Assay Kit (Pierce) and particle size and
number were analyzed using a qNano nanopore-based exosome detection system following the manufacturer's instructions (Izon).
2.6. MiR9 measurement using real time PCR
Total RNA was isolated from serum, MSC and MSC-Exo with TRIzol
(Invitrogen). Then, 2 μg total RNA was used to make cDNA using MMLV (Invitrogen), following standard protocol. Of this cDNA, 2 μl was
used to run a quantitative PCR using the SYBR Green real time PCR
method. Quantitative PCR was performed on a ViiA 7 PCR instrument
(Applied Biosystems) using 3-stage program parameters provided by
the manufacturer, as follows; 2 min at 50 °C, 10 min at 95 °C, and then
40 cycles of 15 s at 95 °C and 1 min at 60 °C. Each sample was tested in
triplicate, and analysis of relative gene expression data using the 2∆∆CT method.
2.7. Experimental groups
Three days after MCAo, T2DM rats were randomized and assigned
to one of the following treatments administered via tail-vein injection:
1) PBS-vehicle control (n = 10); 2) T2DM-MSC-Exo (n = 10, 100 μg
protein concentration ~3 × 1011 exosomes); 3) miR9+/+-T2DMMSC-Exo (n = 6, 100 μg protein concentration ~3 × 1011 exosomes);
4) Nor-MSC-Exo (n = 6, 100 μg protein concentration ~3 × 1011
exosomes). T2DM-sham control group (n = 5) was included as
3
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2.10. Quantification analysis

were cultured in high glucose media (37.5 mmol/l glucose) for 3 days
and treated with 1) Control; 2) + T2DM-MSC-Exo (20 ng); and
3) + miR9+/+-T2DM-MSC-Exo (20 ng); n = 2 chambers/group.
pNFH (mature axon marker) positive axons were photographed at 20×
magnification to obtain 11 fields of view using a video camera interfaced with MCID image analysis system. The average length of axonal
outgrowth of pNFH positive cells was measured using Image J.

All the immunostaining quantification analysis was performed by an
investigator who was blinded to the experimental groups. Six-eight
fields of view of the ischemic boundary zone (IBZ) were digitized under
a 20× objective (Olympus BX40) using a 3-CCD colour video camera
(Sony DXC-970MD) interfaced with an MCID image analysis system
(Imaging Research). For each field of view, positive cell numbers (APC,
NG2, ED1) were counted or the positive stained areas (BS, LFB, albumin-FITC, Prussian blue, ZO-1, ABCA1, IGFR1, IBA1, MMP-9, MCP1) were measured using a built-in densitometry function (MCID image
analysis system) with a uniform threshold set above unstained for all
groups.

3. Statistical analysis
For behavioral tests, two-way repeated Analysis of Variance
(ANOVA) followed by Bonferroni post tests were performed for multiple comparisons. A value of p < .05 was considered significant. Oneway ANOVA was used for the evaluation of histology. “Contrast/estimate” statement was used to test the group difference. If an overall
treatment group effect was detected at p < .05, pair-wise comparisons
were made. All data are presented as mean ± standard error (SE).

2.11. Primary cortical neurons (PCN) axon outgrowth assay
PCNs were obtained from pregnant (day 18) embryonic Wistar rats
(Charles River) and cultured with Neural basal-A medium (GIBCO)
containing 2% B27 medium-supplement in vitro (Chen et al., 2011b;
Ning et al., 2017). To separate axons from neuronal soma, a microfluidic chamber (Xona Microfluidics) was used (Zhang et al., 2013).
PCNs were diluted to a concentration of 15–20 × 106 cells/ml, and
then 10 μl was placed in each microfluidic chamber and allowed to
adhere overnight. The following day, cells were subject to oxygenglucose deprivation (OGD) in a hypoxia chamber (Forma Anaerobic
System, Thermo Scientific) with 37 °C incubator for 2 h. Then, cells

4. Results
4.1. Treatment with T2DM-MSC-Exo significantly improves functional
outcome after stroke in T2DM rats
To test the therapeutic efficacy of T2DM-MSC-Exo, a battery of
function tests including mNSS evaluation and adhesive removal test
were performed. T2DM-MSC-Exo treatment in T2DM stroke rats

Fig. 1. T2DM-MSC-Exo significantly improves neurological functional outcome after stroke in T2DM rats.
a–b) T2DM stroke rats treated with T2DM-MSC-Exo exhibit significantly improved neurological function identified by mNSS test and adhesive removal test compared
to Nor-MSC-Exo treated and PBS treated T2DM stroke rats. Over expression of miR-9 (miR9+/+-T2DM-MSC-Exo) significantly attenuates T2DM-MSC-Exo induced
neurological recovery. c) Treatment with T2DM-MSC-Exo significantly decreases post stroke body weight loss in T2DM rats compared to Nor-MSC-Exo treated,
miR9+/+-T2DM-MSC-Exo and PBS treated T2DM stroke rats. MiR9+/+-T2DM-MSC-Exo does not alter body weight compared to PBS treated T2DM stroke rats. d)
There is no difference in lesion volume between T2DM-MSC-Exo, Nor-MSC-Exo, miR9+/+-T2DM-MSC-Exo and PBS treatment in T2DM rats subjected to stroke. e)
Compared to PBS treated T2DM stroke rats, T2DM-MSC-Exo, Nor-MSC-Exo or miR9+/+-T2DM-MSC-Exo treatment does not significantly affect blood glucose,
cholesterol or triglyceride levels. Sample size: T2DM-MCAo: n = 10; T2DM-MCAo+T2DM-MSC-Exo: n = 10; T2DM-MCAo+Nor-MSC-Exo: n = 6; T2DM-MCAo
+miR9+/+-T2DM-MSC-Exo: n = 6.
4
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significantly improves neurological functional indicated by lower mNSS
score and improved sensorimotor function indicated by adhesive removal test compared to Nor-MSC-Exo treated and control T2DM stroke
rats (p < .05, Fig. 1a–b). T2DM-MSC-Exo treated rats had significantly
lower weight loss after stroke compared to Nor-MSC-Exo treated and
control T2DM stroke rats (p < .05, Fig. 1c), which is typically associated with better stroke outcome (Jönsson et al., 2008). No significant
differences in infarct volume (p > .05, Fig. 1d), blood glucose or lipid
levels were observed (p > .05, Fig. 1e).

4.3. Treatment of T2DM stroke rats with T2DM-MSC-Exo significantly
improves white matter remodeling after stroke
T2DM impairs oligodendrogenesis and white matter remodeling
after cerebral ischemia which affects long term functional recovery (Ma
et al., 2018). Stroke in T2DM rats significantly decreases axon density
(Bielschowsky silver, axon marker, Fig. 3a) and myelin density (luxol
fast blue, myelin marker, Fig. 3b) compared to T2DM sham control rats.
T2DM-MSC-Exo treatment significantly improves axon density
(Fig. 3a), myelin density (Fig. 3b), OL number (Fig. 3c) and OPC
number (Fig. 3d) in the IBZ of T2DM stroke rats compared to control
T2DM stroke rats (p < .05).

4.2. Treatment of T2DM stroke rats with T2DM-MSC-Exo treatment
significantly decreases BBB disruption and hemorrhage after stroke

4.4. T2DM-MSC-Exo treatment significantly decreases inflammatory factor
expression in ischemic brain of T2DM stroke rats

DM stroke is associated with increased BBB leakage and hemorrhage
(Chen et al., 2011c; Cui et al., 2011). Since an intact BBB prevents albumin from entering the brain, we employed FITC-albumin staining to
evaluate the integrity of BBB. The expression of tight junction protein
ZO-1 was evaluated around vessels in the IBZ and hemorrhage was
measured using Prussian blue staining. Stroke in T2DM rats significantly (p < .05) increases BBB leakage (Fig. 2a) and hemorrhage
(Fig. 2b) and decreases tight junction protein ZO-1 expression (Fig. 2c),
compared to T2DM sham control rats. T2DM-MSC-Exo treatment significantly decreases BBB leakage (Fig. 2a) and hemorrhage (Fig. 2b)
while increasing tight junction protein ZO-1 (Fig. 2c) post stroke in
T2DM rats (p < .05).

Consistent with previous findings (Chen et al., 2011c; Ma et al.,
2018; Tureyen et al., 2011), Fig. 4 indicates that T2DM stroke is associated with aggravated inflammatory responses and proinflammatory
microglial/macrophage phenotype. T2DM-MSC-Exo treatment in T2DM
stroke rats significantly decreases activated microglia (IBA1, Fig. 4a),
M1 macrophage (ED1, Fig. 4b), and inflammatory factors MMP-9
(Fig. 4c) and MCP-1 (Fig. 4d) expression in the ischemic brain, compared to control T2DM stroke rats (p < .05).
4.5. Treatment of T2DM stroke rats with T2DM-MSC-Exo significantly
decreases miR-9 expression
To test mechanisms of T2DM-MSC-Exo derived therapeutic benefits

Fig. 2. T2DM-MSC-Exo treatment significantly improves blood brain barrier function and integrity while decreasing brain hemorrhage after stroke in T2DM rats.
Compared to sham T2DM rats, T2DM stroke rats exhibit significantly a) increased BBB leakage identified by FITC-Albumin immunostaining, b) increased brain
hemorrhage identified by Prussian blue immunostaining and c) decreased tight junction protein ZO-1 expression in the ischemic brain. Compared to PBS treated
T2DM-stroke rats, T2DM-MSC-Exo treated T2DM stroke rats exhibit significantly a) decreased BBB leakage, b) decreased brain hemorrhage and c) increased tight
junction protein ZO-1 expression in the ischemic boundary zone. Over expression of miR9 (miR9+/+-T2DM-MSC-Exo) does not significantly inhibit T2DM-MSC-Exo
induced BBB protection or alter brain hemorrhage in T2DM stroke rats. Scale bar: 0.05 mm. Sample size: T2DM sham: n = 5; T2DM-MCAo: n = 10; T2DM-MCAo
+T2DM-MSC-Exo: n = 10; T2DM-MCAo+miR9+/+-T2DM-MSC-Exo: n = 6. *p < .05. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
5
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Fig. 3. T2DM-MSC-Exo treatment significantly improves white matter remodeling after stroke in T2DM rats.
Compared to sham T2DM rats, T2DM stroke rats exhibit significantly a) decreased axon density identified by Bielschowsky silver staining and b) decreased myelin
density identified by Luxol fast blue staining in the ischemic brain. Compared to PBS treated T2DM stroke rats, T2DM-MSC-Exo treatment significantly increases a)
axon density, b) myelin density, c) oligodendrocyte cell number identified by APC immunostaining and d) oligodendrocyte progenitor cell number identified by NG2
immunostaining in the ischemic boundary zone of T2DM stroke rats. Treatment of T2DM stroke rats with miR9+/+-T2DM-MSC-Exo significantly decreases axon
density, myelin density, oligodendrocyte number and oligodendrocyte progenitor cell number in the ischemic boundary zone compared to T2DM-MSC-Exo treated
T2DM stroke rats. However, miR9+/+-T2DM-MSC-Exo treatment increases myelin density, oligodendrocyte number and oligodendrocyte progenitor cell number in
the ischemic boundary zone compared to PBS treated T2DM stroke rats. Scale bar: 0.05 mm. Sample size: T2DM sham: n = 5; T2DM-MCAo: n = 10; T2DM-MCAo
+T2DM-MSC-Exo: n = 10; T2DM-MCAo+miR9+/+-T2DM-MSC-Exo: n = 6. *p < .05. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)

in T2DM stroke, we tested the expression of several miRs that are associated with T2DM and stroke in serum of T2DM stroke rats treated
with PBS and T2DM-MSC-Exo. As shown in Fig. 5a–b, we found that
miR-9 expression was significantly decreased in T2DM-MSCs and
T2DM-MSC-Exo compared to MSCs and MSC-Exo, respectively. Fig. 5c
shows that stroke in T2DM rats significantly increases serum miR-9
expression compared to T2DM sham rats. Our data also show that
compared to PBS treated T2DM stroke rats, miR-9 expression is significantly decreased in serum of T2DM-MSC-Exo treated T2DM stroke
rats and significantly increased in serum of T2DM stroke rats treated
with miR9+/+-T2DM-MSC-Exo. ISH using LNA probes specific for
miR-9 in brain sections from T2DM-stroke rats indicates that miR-9 is
expressed in the nucleus and cytoplasm of brain cells, while U6 was
positive in the nucleus and scramble probe did not detect any signal
(Fig. 5d). Stroke in T2DM rats increases miR-9 expression in the brain
and treatment with T2DM-MSC-Exo decreases miR-9 expression in the
brain. Treatment with miR9+/+-T2DM-MSC-Exo increases miR-9 expression. To identify the neurovascular locations of cerebral miR-9
expression, after ISH, immunofluorescent staining was performed with

antibody against GFAP (astrocyte marker), vWF (endothelial cell
marker) and NeuN (neuron marker). We observe co-localization of miR9 with neurons, endothelial cells and astrocytes (Supplementary Fig. 3).
4.6. MiR-9 may partially mediate T2DM-MSC-Exo induced
neurorestorative effects in T2DM stroke rats
To test the role of miR-9 in mediating the therapeutic effects of
T2DM-MSC-Exo in T2DM stroke rats, we evaluated the effects of
miR9+/+T2DM-MSC-Exo treatment. Our data indicate that miR9+/
+-T2DM-MSC-Exo treatment fails to improve neurological function
(Fig. 1a–b) and does not improve BBB integrity (Fig. 2a) or tight
junction protein expression (Fig. 2c) compared to control T2DM stroke
rats. However, T2DM stroke rats treated with miR9+/+T2DM-MSCExo exhibit significantly decreased hemorrhage (Fig. 2b) and improved
myelin density (Fig. 3b) and oligodendrogenesis (Fig. 3c–d) compared
to control T2DM stroke rats; and miR9+/+T2DM-MSC-Exo treatment
improves primary cortical neuron (PCN) axon outgrowth compared to
control group (Fig. 5e). Overexpression of miR-9 significantly
6
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Fig. 4. T2DM-MSC-Exo treatment significantly decreases cerebral inflammation after stroke in T2DM rats.
Compared to sham T2DM rats, T2DM stroke rats exhibit significantly a) increased activated microglia identified by IBA1 immunostaining, b) increased M1 macrophage identified by ED1 immunostaining and c) increased inflammatory factors MMP-9 and MCP-1 expression in the ischemic brain. Compared to PBS treated
T2DM stroke rats, T2DM-MSC-Exo treatment significantly decreases a) activated microglia, b) M1 macrophage and c–d) MMP-9 and MCP-1 expression in the
ischemic brain of T2DM stroke rats. Treatment of T2DM stroke rats with miR9+/+-T2DM-MSC-Exo significantly increases activated microglia, M1 macrophage and
MMP-9 expression compared to T2DM-MSC-Exo treated T2DM stroke rats. Scale bar: 0.05 mm. Sample size: T2DM sham: n = 5; T2DM-MCAo: n = 10; T2DM-MCAo
+T2DM-MSC-Exo: n = 10; T2DM-MCAo+miR9+/+-T2DM-MSC-Exo: n = 6. *p < .05.

attenuates T2DM-MSC-Exo treatment induced improvement in axon
density, myelin density, OL and OPC number (Fig. 3a–d), and PCN axon
outgrowth (Fig. 5e) compared to the T2DM-MSC-Exo treated group.
Overexpression of miR-9 significantly attenuates T2DM-MSC-Exo
treatment induced anti-inflammatory effects and increases IBA1 and
MMP9 expression compared to T2DM-MSC-Exo treated group
(Fig. 4a,c). Therefore, it is likely that miR-9 partially contributes to
T2DM-MSC-Exo treatment induced neurorestorative effects and other
signaling pathways are also involved.

oligodendrocytes (CNPase) or astrocytes (GFAP) in the IBZ (Supplementary Fig. 2). However, miR9+/+T2DM-MSC-Exo treatment fails to
increase ABCA1 and IGFR1 expression (Fig. 6a,b) compared to T2DMMSC-Exo treated T2DM stroke rats.
5. Discussion
In this study, we have demonstrated for the first time that treatment
of T2DM stroke with exosomes derived from MSCs of T2DM rats exerts
therapeutic effects resulting in neurological functional recovery compared to Nor-MSC-Exo treated or PBS treated control T2DM stroke rats.
Our data indicate that T2DM-MSC-Exo treatment attenuates BBB
leakage, hemorrhage, weight loss, and inflammatory responses, while
increasing white matter remodeling. T2DM-MSC-Exo induced therapeutic effects maybe partially mediated by decreasing miR-9 and upregulating ABCA1-IGFR1 pathway.
Neurorestorative therapies aim to improve neurological function by
promoting brain remodeling and plasticity after stroke. In non-diabetic
rats subjected to stroke, both MSCs and MSC-Exo treatment improves
neurological outcome by promoting neurogenesis, angiogenesis, neurite
remodeling and neurovascular remodeling (Chen et al., 2003; Xin et al.,

4.7. Treatment of T2DM stroke rats with T2DM-MSC-Exo significantly
increases ABCA1 and IGFR1 expression after stroke
ABCA1 and IGF1 are targets of miR-9 (D'Amore et al., 2018). T2DM
is associated with reduced ABCA1 gene expression, protein and function (Patel et al., 2011; Tang et al., 2020). Data in Fig. 6a–b show that
stroke in T2DM rats significantly decreases ABCA1 expression in the
brain compared to T2DM sham rats and T2DM-MSC-Exo treatment in
T2DM stroke rats significantly increases ABCA1 and IGFR1 expression
compared to T2DM-MCAo control. We also found that ABCA1 expression co-localizes mostly with neurons (NeuN) compared to
7
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Fig. 5. Treatment of T2DM stroke rats with T2DM-MSC-Exo significantly decreases serum miR-9 expression. MiR-9 may mediate T2DM-MSC-Exo induced axonal
outgrowth.
MiR-9 expression is significantly decreased in a) T2DM-MSCs compared to non-DM MSCs and b) exosomes derived from T2DM-MSCs compared to exosomes derived
from non-DM MSCs. c) Compared to T2DM sham rats, T2DM stroke rats exhibit significantly increased serum miR-9 expression. Compared to PBS treated T2DM
stroke rats, miR-9 expression is significantly decreased in serum of T2DM-MSC-Exo treated T2DM stroke rats and significantly increased in serum of T2DM stroke rats
treated with miR9+/+-T2DM-MSC-Exo. d) In situ hybridization using LNA probes specific for miR-9 in brain sections from T2DM-stroke rats indicates that miR-9 is
expressed in the nucleus and cytoplasm of brain cells, while U6 was positive in the nucleus and scramble probe did not detect any signal. Stroke in T2DM rats
increases miR-9 expression in the brain and treatment with T2DM-MSC-Exo decreases miR-9 expression in the brain. Treatment with miR9+/+-T2DM-MSC-Exo
increases miR-9 expression. e) In PCNs subject to ischemia and high glucose conditions, T2DM-MSC-Exo and miR9+/+-T2DM-MSC-Exo treatment significantly
improve axonal outgrowth compared to control group. However, miR9+/+-T2DM-MSC-Exo significantly decreases PCN axon outgrowth compared to T2DM-MSCExo treated group. Sample size: T2DM sham: n = 5; T2DM-MCAo: n = 10; T2DM-MCAo+T2DM-MSC-Exo: n = 10; T2DM-MCAo+miR9+/+-T2DM-MSC-Exo:
n = 6. *p < .05.

2013a). Our data indicate that T2DM-MSC-Exo but not Nor-MSC-Exo
improves neurological outcome in T2DM rats subjected to stroke. This
is consistent with our previous study in which treatment of T1DM
stroke rats with DM-MSCs improved neurological functional outcome,
BBB integrity, vascular remodeling and white matter remodeling, while
treatment of T1DM stroke with Nor-MSCs did not improve neurological

outcome or promote neurorestorative effects (Chen et al., 2011e; Cui
et al., 2016). Significant improvement in neurological outcome after
treatment of T2DM stroke with human MSCs, rat-non-DM MSCs and ratnon-DM MSC-conditioned medium has been previously reported (Hu
et al., 2016; Xiang et al., 2017; Yan et al., 2016). In humans as well as
rats, MSCs derived from normal or diabetic subjects exhibit similar
8
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Fig. 6. Treatment of T2DM stroke rats with T2DM-MSC-Exo significantly increases brain ABCA1 and IGFR1 expressions.
a) Compared to T2DM sham rats, T2DM stroke rats exhibit significantly decreased ABCA1 expression in the brain. T2DM-MSC-Exo treatment in T2DM stroke rats
significantly increases ABCA1 expression compared to T2DM stroke rats. b) T2DM-MSC-Exo treatment in T2DM stroke rats significantly increases IGFR1 expression
compared to T2DM stroke rats. However, miR9+/+T2DM-MSC-Exo treatment significantly decreases ABCA1 and IGFR1 expression compared to T2DM-MSC-Exo
treated T2DM stroke rats. Scale bar: 0.05 mm. Sample size: T2DM sham: n = 5; T2DM-MCAo: n = 10; T2DM-MCAo+T2DM-MSC-Exo: n = 10; T2DM-MCAo
+miR9+/+-T2DM-MSC-Exo: n = 6. *p < .05.

found that stroke in T2DM rats significantly increases BBB leakage,
decreases tight junction protein expression, decreases axon and myelin
density, reduces the number of OLs and OPCs and increases inflammation in the brain compared to T2DM sham rats. These data are
consistent with prior reports that T2DM-stroke increases pathological
vascular remodeling, increases hemorrhagic transformation, aggravates
ischemic injury and exacerbates white matter damage and inflammation in the brain (Chen et al., 2011a; Ergul et al., 2007). We also found
that T2DM stroke rats treated with T2DM-MSC-Exo exhibit significantly
increased tight junction protein expression and improved BBB function
compared to control T2DM-stroke rats. Improved BBB function is a key
factor in improving neurological outcome and promoting neurorestorative effects in diabetic stroke animals and has been reported in
MSC and human umbilical cord blood cell treatments of diabetic stroke
(Cui et al., 2016; Venkat et al., 2018; Yan et al., 2015; Yan et al., 2016).
Compared to non-diabetic stroke mice, T2DM stroke mice exhibit significantly greater demyelination, impaired oligodendrogenesis and
worse functional outcome at 35 days after ischemic stroke (Ma et al.,
2018). Therefore, improving white matter remodeling is essential to
improve long term neurological functional outcome. Our data show
that T2DM-MSC-Exo treatment of stroke in T2DM rats significantly
improves axon and myelin density and improves oligodendrogenesis
compared to control T2DM stroke rats.
A leaky BBB aggravates inflammatory response by facilitating invasion of peripheral immune cells, inflammatory factors and macrophages thereby creating an inhospitable environment for brain repair
(Jiang et al., 2018). Inflammatory factor MMP-9 is elevated after stroke
and has been implicated in aggravating BBB disruption, neuronal death,
myelin degradation and white matter injury (Clark et al., 1997; Ji et al.,
2017). Particularly in T2DM stroke mice, increased MMP-9 exacerbates
white matter injury (Chen et al., 2011a). Inflammatory factor MCP-1 is
elevated in serum of diabetic patients as well as from stroke patients
(Arakelyan et al., 2005; Vinagre et al., 2014). Compared to wild type
control, MCP-1 deficient mice (MCP-1−/−), and rats with non-functional MCP-1 develop significantly smaller infarct volume after stroke
and have significantly lower accumulation of phagocytic M1 macrophage in the IBZ (Bose and Cho, 2013; Hughes et al., 2002). In response
to ischemia, microglia become reactive and release of cytotoxic factors
and oxidative metabolites which contribute to neuronal injury and

morphology, surface marker expression, growth kinetics and differentiation potential in-vitro (Gabr et al., 2013; José et al., 2017;
Yaochite et al., 2016). However, the secretome of MSCs differs between
normoglycemic and hyperglycemic conditions (Morris et al., 2018;
Ribot et al., 2017). By employing T2DM Zucker diabetic fatty rats and
Zucker LEAN littermates as non-DM control, it has been demonstrated
that short-term diabetes alters MSC secretome composition and promotes angiogenic capabilities (Ribot et al., 2017). Priming or preconditioning MSCs with hypoxia, growth factors, high glucose, oxidative stress, LPS stimulation etc. improves the therapeutic effects of
MSCs in various diseases (Noronha et al., 2019). DM-MSCs secrete soluble, bioactive, angiogenic and chemotactic mediators which promote
endothelial cell tube-like formation and migration (Ribot et al., 2017).
Proteomic analysis of non-DM-MSCs and DM-MSCs conditioned media
also showed differences in proteins related to extracellular matrix remodeling and glucose metabolism (Ribot et al., 2017). Among these
factors, vascular endothelial growth factor (VEGF) expression levels are
significantly reduced in DM-MSCs compared to Non-DM-MSCs (Khan
et al., 2013; Ribot et al., 2017; Zacharek et al., 2007). VEGF is a key
mediator of angiogenesis and vascular permeability (Keck et al., 1989).
While increasing VEGF in the recovery phase of non-DM stroke is associated with improved angiogenesis and neurological function, in
diabetic stroke, elevated VEGF expression is associated with increased
BBB permeability and brain swelling, resulting in worse outcome and
larger infarct size (Kim et al., 2018; Zhang et al., 2000). However, it is
likely that increased BBB leakage and/or brain hemorrhage override
potential beneficial effects of Nor-MSC/Nor-MSC-Exo in DM stroke.
Thus, variations in secreted factors that mediate vascular remodeling
and stabilization, and BBB integrity may contribute to therapeutic differences between nor-MSC-Exo and DM-MSC-Exo.
Poor neurological functional outcome in diabetic stroke has been
attributed in part to microvascular dysfunction, increased BBB permeability and aggravated inflammatory responses (Chen et al., 2011b;
Ding et al., 2015; Field et al., 2015; Husseini et al., 2017; Uzu et al.,
2010). In addition, T2DM results in greater structural and functional
disruption of white matter after stroke which is associated with worse
long term functional outcome (Ma et al., 2018). Tight junction proteins
such as ZO-1, claudin-5 and occludin play critical roles in maintaining
an intact and functioning BBB (Ueno, 2007). Similarly, in this study we
9
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elevated inflammatory status in the ischemic brain (Kim and Cho,
2016). Following ischemic stroke, hyperglycemia favors pro-inflammatory state of macrophages and inhibits macrophage polarization
to a non-inflammatory state (Khan et al., 2016; Ma et al., 2018). Hyperglycemia shifts microglia to an inflammatory M1 phenotype which
impairs OPC differentiation and maturation (Ma et al., 2018). In T2DM
stroke mice, proinflammatory microglia/macrophage responses impairs
oligodendrogenesis and inhibits white matter repair (Ma et al., 2018).
Ablation of peripheral monocytes inhibits the adverse effects of hyperglycemia indicating that monocytes play an important role in the
pathological cascade following stroke in hyperglycemic mice (Khan
et al., 2016). Our data show that T2DM stroke rats treated with T2DMMSC-Exo exhibit significantly decreased IBA1, ED1, MMP-9 and MCP-1
expression in the ischemic brain while increased tight junction protein
and improved BBB integrity.
MiRs are emerging as key players in the pathogenesis of T2DM and
stroke and subsequent vascular and white matter damage (Shantikumar
et al., 2012; Zampetaki et al., 2010; Zampetaki and Mayr, 2012). It has
been previously demonstrated that MSC-Exo and their cargo miRs
promote neurite remodeling and functional recovery after stroke in rats
(Xin et al., 2012a; Xin et al., 2013b). In a cohort of newly diagnosed
T2DM patients, 7 serum miR's including miR-9 were upregulated (Kong
et al., 2011). MiR-9 is one of the most abundant miRs in the developing
and adult vertebrate brain (Coolen et al., 2013). Under normal conditions, miR-9 expression in blood is very low (Ogata et al., 2015). Given
the specificity of miR-9 to adult CNS, release of miR-9 into the circulation is considered an indicator of neural damage and neurotoxicity
(Hachisuka et al., 2014; Ji et al., 2016; Ogata et al., 2015; Xue et al.,
2018a). In acute ischemic stroke patients, serum and serum exosomal
miR-9 expression were significantly increased compared to healthy
control patients (Ji et al., 2016; Xue et al., 2018b). Increased serum
miR-9 and serum exosomal miR-9 expression were also found to positively correlate with the increased infarct volume, poor neurological
outcome and increased expression of inflammatory factors in serum
compared to the healthy control group (Ji et al., 2016; Xue et al.,
2018a). In these patients, it is likely that the increased miR-9 in peripheral blood is derived from the injured brain tissue (Ji et al., 2016;
Xue et al., 2018b). Likewise, our data indicate that stroke in T2DM rats
significantly increases serum and brain miR-9 expression. In addition,
DM-MSCs and DM-MSC-Exo exhibit reduced miR-9 expression compared to MSCs and MSC-Exo, respectively, and T2DM-MSC-Exo treatment significantly decreases serum and brain miR-9 expression.
Decreasing miR-9 increases ABCA1 expression (D'Amore et al.,
2018). ABCA1 is expressed in cells that constitute the neurovascular
unit and thereby plays an important role in maintenance of the BBB and
stability of the neurovascular unit (Kim et al., 2006). ABCA1 is highly
expressed in neurons, microglia, astrocytes and OLs (Kim et al., 2006;
Koldamova et al., 2003) and is required for myelination, dendritic
outgrowth and synaptic activity (Karasinska et al., 2009). We have
previously demonstrated that deficiency of ABCA1 in brain induces
worse neurological functional deficits after stroke, increases BBB
leakage and aggravates demyelination, OL loss, axonal injury and
neurofilament loss (Cui et al., 2015; Cui et al., 2017; Wang et al., 2018).
Our data show that treatment with T2DM-MSC-Exo significantly increases ABCA1 and IGFR1 expression compared to T2DM stroke rats.
We also found that, in T2DM stroke rats treated with T2DM-MSC-Exo,
ABCA1 expression co-localizes mostly with neurons (NeuN) compared
to oligodendrocytes (CNPase) or astrocytes (GFAP) in the ischemic
boundary zone. In a previous study, transgenic mice lacking brain
ABCA1 (ABCA1-B/-B) as well as mice selectively lacking ABCA1 in
neurons (ABCA1-N/-N) or astrocytes (ABCA1-Ast/-Ast) were examined for
neuroinflammation in the brain (Karasinska et al., 2013). ABCA1-B/-B
mice exhibited cortical astrogliosis and elevated inflammatory gene
expression profile, ABCA1-N/-N mice exhibited cortical astrogliosis
without changes in inflammatory genes while ABCA1-Ast/− Ast mice did
not develop astrogliosis or elevated expression of inflammatory markers

(Karasinska et al., 2013). This indicates that loss of neuronal ABCA1
alone can lead to increased presence of reactive astrocytes without
microglial activation and coordinated ABCA1 activity across neurons
and glial cells affects neuroinflammation and neurodegeneration in the
brain (Karasinska et al., 2013). IGF1 mediates brain growth and development, as well as neurorestorative effects such as myelination,
neurogenesis and oligodendrogenesis. IGF1 also exerts neuroprotective
effects and improves BBB integrity post stroke. IGF1 decreases cholesterol efflux via ABCA1 and scavenger receptor class B type I expression.
Hence the ABCA1 and IGF1 pathway may play a key role in neurorestorative post stroke.
To test the role of miR-9 in mediating T2DM-MSC-Exo derived
therapeutic effects after T2DM stroke in rats, we treated a group of
T2DM stroke rats with miR9+/+-T2DM-MSC-Exo. Our data indicate
that miR9+/+-T2DM-MSC-Exo treatment fails to improve neurological function or BBB integrity and significantly attenuates T2DM-MSCExo induced WM remodeling and anti-inflammatory effects. In response
to ischemic injury to the brain, microglia become activated, undergo
morphological change, express surface markers similar to macrophages
and circulating monocytes, release proinflammatory factors, and function as phagocytes (Taylor and Sansing, 2013; Yenari et al., 2010).
While the activation of microglia evolves over the hours and days following ischemic injury, their phagocytic function facilitates debris removal and neurorepair in the ischemic brain, yet, their generation of
proinflammatory cytokines, cytotoxic factors and oxidative metabolites
contribute to neuronal injury and secondary brain damage (Kim and
Cho, 2016; Taylor and Sansing, 2013; Yenari et al., 2010). Microglia
under normal conditions do not express miR-9; however, in response to
activation such as LPS stimulation, Iba-1 positive microglia express
mature miR-9 (Yao et al., 2014). MiR-9 mediated activation of rat
primary microglial cells shift these cells to M1 phenotype and increases
the expression of proinflammatory mediators such as interleukin (IL)1β, IL-6, tumor-necrosis factor-α (TNF-α), MCP-1 and nitric oxide (NO)
(Yao et al., 2014). Our data indicate that T2DM stroke is associated
with increased miR9 and aggravated inflammatory responses, and increased proinflammatory microglial/macrophage phenotype. However,
treatment with T2DM-MSC-Exo significantly decreases miR9 and
thereby decreases activated microglia and M1 macrophage and inflammatory factors MMP-9 and MCP-1 expression in the ischemic brain,
compared to control T2DM stroke rats. Conversely, miR9+/+T2DMMSC-Exo treatment exacerbates inflammatory responses with increased
IBA1, and MMP-9 expression compared to T2DM-MSC-Exo treated
T2DM stroke rats. Thus, decreasing miR-9 may reduce inflammatory
responses and thereby reduce secondary brain damage and contribute
to the T2DM-MSC-Exo induced improvement in stroke outcome in
T2DM rats. In‑neonatal rat neuronal cells, transfection of neuronal cells
with a miR-9 mimic increased OGD induced apoptosis while transfection with a miR-9 inhibitor decreased OGD induced neuronal apoptosis
(Xue et al., 2018a). We found that in PCN's subject to OGD under high
glucose conditions, miR-9 overexpression attenuates T2DM-MSC-Exo
induced attenuates axon outgrowth. However, the effects on BBB integrity between T2DM-MSC-Exo and miR9+/+-T2DM-MSC-Exo
treatments are not significantly different, and miR9+/+-T2DM-MSCExo treatment improves myelination in T2DM-MCAo rats and improves
PCN axonal outgrowth compared to ischemic control group. Therefore,
it is likely that miR-9 and its targets such as ABCA1 only partially
contribute to T2DM-MSC-Exo treatment induced neurorestorative effects, and it is likely that other signaling pathways are also involved.
The miR-145/ABCA1 pathway was found to play a major role in DMMSCs treatment induced neurorestorative effects after stroke in T1DM
rats (Cui et al., 2016). Both miR-145 and miR-9 can regulate ABCA1
expression, and it is likely that in addition to miR-9; other miR's such as
miR-145 may contribute to therapeutic effects of T2DM-MSC-Exo
treatment in T2DM stroke. Further studies are warranted to investigate
mechanisms of T2DM-MSC-Exo derived therapeutic effects in T2DM
stroke.
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Mobilization of stem cells from bone marrow to peripheral blood
followed by migration to injured brain tissue contributes to early endogenous repair mechanisms in the ischemic brain (Borlongan, 2011;
Courties et al., 2015; Rochefort et al., 2006; Wang et al., 2014; Zhang
et al., 2002). In patients with acute ischemic stroke, there was a significant increase in non-apoptotic, MSC-derived microparticles in the
circulation indicating that stroke induces mobilization of bone marrow
derived MSCs and MSC derived microparticles (Kim et al., 2012). Induction of transient MCAo in mice rapidly activates bone marrow
myeloid cells, releases CXCR2-positive granulocytes from the bone
marrow and increases bone marrow leukocyte response (Denes et al.,
2011). Stroke also alters the sub-population of bone marrow derived
mononuclear cells and their release of bioactive factors and cytokines
which exert anti-apoptotic, pro-angiogenic and pro-neurogenic effects
as well as modulate pro-inflammatory and anti-inflammatory responses
(Yang et al., 2012). Exogenous stem cell therapy also activates and
facilitates migration of endogenous stem cells from neurogenic niches
to injured brain tissue to promote repair and recovery (Crowley and
Tajiri, 2017; Tajiri et al., 2013; Yoo et al., 2008). Therefore, in addition
to the therapeutic effects of exogenously administered T2DM-MSC-Exo,
it is likely that the endogenous stem cells and their exosomes also
contribute to improvement of neurological outcome and neurorestorative effects in T2DM rats.
There are a few limitations to this study. The source of MSCs is
known to influence the biological function of MSCs (Bonab et al.,
2006). We have previously reported that non-diabetic MSCs administered at 1 day after stroke have adverse effects in T1DM stroke rats
(Chen et al., 2011d), while human MSCs administered at 3 days after
stroke significantly improves neurological function and promotes neurorestorative effects after stroke in T2DM rats (Yan et al., 2016). Here
we show that T2DM-MSC-Exo but not Nor-MSC-Exo, improves neurological function after stroke in T2MD rats. It is important to investigate
the mechanisms by which treatment with MSCs and MSC-Exo from
different sources affect stroke outcome.
The changes in BBB integrity, white matter remodeling and inflammatory responses after treatment with T2DM-MSC-Exo in T2DM
stroke rats have been evaluated using immunohistochemical staining
and analysis, and further biochemical analyses are warranted. We have
not investigated sex effects on T2DM-MSC-Exo treatment for T2DMstroke in rats. We are aware that the optimized treatment protocol and
neurovascular responses for males may not be the same for females.
Therefore, investigations of the effect of sex differences of T2DM-MSCExo treatment for T2DM stroke are warranted.
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